F. van Gaalen

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Sofía Ramiro, Elena Nikiphorou, Alexandre Sepriano et al. · Annals of the Rheumatic Diseases · 2022 · 929 citations · Full text

Medicine, Pharmacotherapy, Clinical Pharmacology +10

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study

F. van Gaalen, Suzanne P. Linn-Rasker, W J van Venrooij et al. · Arthritis & Rheumatism · 2004 · 642 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA–DRB1 shared epitope for antibodies to citrullinated proteins

T. Huizinga, Christopher I. Amos, Annette H M van der Helm–van Mil et al. · Arthritis & Rheumatism · 2005 · 589 citations

Life Sciences, Clinical Sciences, Immunology +17

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study

Anna Moltó, Adrien Etcheto, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2015 · 264 citations

Medicine, Internal Medicine, Epidemiology +12

Rheumatoid arthritis is a heterogeneous disease: Evidence for differences in the activation of the STAT‐1 pathway between rheumatoid tissues

Tineke C. T. M. van der Pouw Kraan, F. van Gaalen, Pia V. Kasperkovitz et al. · Arthritis & Rheumatism · 2003 · 262 citations · Full text

Life Sciences, Immunology, Molecular Biology +15